Gliclazide MR in the structure of antihyperglycemic therapy according to the data of Moscow region diabetes register

Gliclazide MR in the structure of antihyperglycemic therapy according to the data of Moscow region diabetes register

Background: Sulfonylureas (SU) are often used for second and third line type 2 diabetes mellitus (T2DM) therapy. Currently, there are no unified recommendations governing the choice of drugs for the second line therapy. This requires clarification.Aim: To examine Moscow Region DM register data for a...

Full description

Saved in:

Bibliographic Details
Main Authors:	I. V. Misnikova, Yu. A. Kovaleva, V. A. Gubkina, A. V. Dreval
Format:	Article
Language:	English
Published:	Endocrinology Research Centre 2022-05-01
Series:	Сахарный диабет
Subjects:	type 2 diabetes mellitus the structure of glucose-lowering therapy non-insulin drugs sulfonylureas gliclazide mr
Online Access:	https://www.dia-endojournals.ru/jour/article/view/12799
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

The place of gliclazide MB in modern treatment strategies for patients with type 2 diabetes mellitus
by: N. A. Petunina, et al.
Published: (2024-09-01)

Results of a 12-month follow-up of patients with type 2 diabetes mellitus after hospitalization with COVID-19: gliclazide MR use in the hospital and metabolic status at the posthospital stage
by: T. A. Nekrasova, et al.
Published: (2023-07-01)

Indonesia DIA-RAMADAN Study: A Real-life, Prospective and Observational of Gliclazide MR in Type-2 Diabetes Patients During Ramadan Fasting
by: Soebagijo Adi Soelistijo, et al.
Published: (2022-04-01)

Current data on the effectiveness of gliclazide and molecular mechanisms of action of the drug
by: Nina A. Petunina, et al.
Published: (2020-12-01)

Results of the ADVANCE trial and interventional observational program ADVANCE-ON: whether our understanding of the relationship of glycemic factors and the risk of vascular complications in patients with type 2 diabetes has changed?
by: Marina Vladimirovna Shestakova, et al.
Published: (2015-12-01)

The glucose-lowering therapy structure in special groups of type 2 diabetes mellitus patients based on data from the Moscow region register
by: Inna V. Misnikova, et al.
Published: (2019-08-01)

Review of the results of the EASYDia international observational study. The effect of dose titration of diabeton MR on the effectiveness of treatment of type 2 diabetes
by: Natalia Р. Trubitsyna, et al.
Published: (2019-06-01)

Simultaneous HPLC of Metformin, Glipizide and Gliclazide, and Metformin Uptake and Protection of HEI-OC1 from Hyperglycaemia
by: Ahmed Gedawy, et al.
Published: (2024-11-01)

Low risk of hypoglycemia and high efficacy of gliclazide MB: results of recent studies
by: I. V. Kononenko, et al.
Published: (2021-11-01)

Efficacy and Safety of Gliclazide versus Glimepiride in T2DM Patients: A Systematic Review
by: Rifika Bansal, et al.
Published: (2025-05-01)

Gliclazide protects ionizing radiation-induced intestinal injury in mice by inhibiting oxidative stress and caspase-3
by: Soroush Arzani, et al.
Published: (2024-12-01)

Haemostasiologic effects of various glucose-lowering medications in type 2 diabetes mellitus
by: G. G. Petrik, et al.
Published: (2010-04-01)

Hemostasis effects of various glucose-lowering medications and angiopathy prevention
by: G. G. Petrik, et al.
Published: (2011-06-01)

Initiation of insulin therapy in patients with type 2 diabetes: An observational study
by: Zerovnik Spela, et al.
Published: (2022-03-01)

Clinical efficacy of gliclazide with modified release after myocardial infarction in patients with concomitant type 2 diabetes
by: N. S. Mykhailovska
Published: (2014-04-01)

Myricetin Amplifies Glucose–Stimulated Insulin Secretion via the cAMP-PKA-Epac-2 Signaling Cascade
by: Akhtar Ali, et al.
Published: (2025-06-01)

CARDIOVASCULAR COMPLICATIONS AND CARBOHYDRATE METABOLISM IN CORONARY SHUNTING “OFF-PUMP” ACCORDING TO THE REGIMEN OF GLUCOSE LOWERING TREATMENT IN ISCHEMIC HEART DISEASE AND DIABETES
by: S. Yu. Borodashkina, et al.
Published: (2016-02-01)

Initial glucose-lowering therapy and risks of overall and cardiovascular mortality, myocardial infarction and stroke in patients with type2 diabetes
by: Inna Vladimirovna Misnikova, et al.
Published: (2009-12-01)

Optimization of therapy of type 2 diabetes mellitus with the oral hypoglycemic agent glimepiride
by: Tatiana Ivanovna Romantsova, et al.
Published: (2010-03-01)

Risk of oncological diseases in patients with diabetes mellitus
by: Gagik Radikovich Galstyan
Published: (2009-12-01)

“Low Dose MR” Dixon Technique for Imaging FDG PET-MR Lymphoma
by: Musa Ali Mufti, et al.
Published: (2022-06-01)

Prescription characteristics of the insulin glargine plus lixisenatide fixed-ratio combination in real-world clinical practice according to the Registry of Diabetes Mellitus in the Moscow Region
by: Inna V. Misnikova, et al.
Published: (2024-12-01)

Early intensification of therapy for type 2 diabetes mellitus and achievement of the target level of glycohemoglobin HbA<sub>1c</sub> are necessary factors to reduce the risk of micro- and macrovascular complications
by: M. S. Shamkhalova, et al.
Published: (2023-08-01)

Russian Association of Endocrinologists reports commencement of Glimecomb clinical use
by: Editorial team Diabetes Mellitus
Published: (2011-12-01)

Leptin secretion and severity of glycemic disorders in women with body weight excess
by: Alexander Vasil'evich Dreval', et al.
Published: (2013-06-01)

Type 2 diabetes therapy at the time of diagnosis. Glimepiride: property, efficiency, safety
by: Olga Mikhailovna Smirnova
Published: (2009-03-01)

Challenges in diagnosis and treatment of KCNJ11-MODY
by: Juliana Gonçalves, et al.
Published: (2024-12-01)

Molecular basis underpinning MR1 allomorph recognition by an MR1-restricted T cell receptor
by: Richard J. Suckling, et al.
Published: (2025-03-01)

Development of in-house software to process real-time cine magnetic resonance images acquired during 1.5 T MR-guided radiation therapy
by: Jiwon Sung, et al.
Published: (2025-08-01)

Pharmacoepidemiological analysis of type 1 diabetes mellitus insulin therapy (According to the Moscow segment of the State Register of Diabetes Mellitus)
by: M. B. Antsiferov, et al.
Published: (2023-11-01)

Effectiveness of the original trimetazidine MR in patients with stable coronary heart disease and angina attacks resistant to trimetazidine generics (ETALON study)
by: A. V. Fendrikova, et al.
Published: (2011-08-01)

Diabetes mellitus in Russian Federation: prevalence, morbidity, mortality, parameters of glycaemic control and structure of glucose lowering therapy according to the Federal Diabetes Register, status 2017
by: Ivan I. Dedov, et al.
Published: (2018-08-01)

Effect of polyphenolic complexes wood and cellular culture Maackia amurensis on the MR тomography performance of a liver
by: V. S. Chuchalin, et al.
Published: (2011-06-01)

A cost-effectiveness analysis of intensive therapy of type 2 diabetes mellitus (results of Steno-2 study)
by: Yury Shavkatovich Khalimov, et al.
Published: (2011-06-01)

Mr-lac3 and Mr-lcc2 in <i>Metarhizium robertsii</i> Regulate Conidiation and Maturation, Enhancing Tolerance to Abiotic Stresses and Pathogenicity
by: Qiaoyun Wu, et al.
Published: (2025-02-01)

Optimizing screening procedures for early detection of glycemic disorders
by: Inna Vladimirovna Misnikova, et al.
Published: (2014-03-01)

Development of single and multi-coil MR damper subjected to cyclic loading for structural vibration control
by: Daniel Cruze, et al.
Published: (2024-01-01)

A human cell model for dynamic testing of MR contrast agents
by: Anne-Lise Aulanier, et al.
Published: (2011-02-01)

Atlas of Diabetes Register in Russian Federation, status 2018
by: Ivan I. Dedov, et al.
Published: (2019-11-01)

Diabetes mellitus in the Russian Federation: dynamics of epidemiological indicators according to the Federal Register of Diabetes Mellitus for the period 2010–2022
by: I. I. Dedov, et al.
Published: (2023-05-01)